Tarawneh et al. (2015) studied the usefulness of various CSF markers (e.g., Aβ42, p-tau) in predicting rates of whole-brain neurodegeneration and whole-brain atrophy in 23 subjects with mild AD and 64 cognitively normal-aged control subjects from The Charles F. and Joanne Knight Alzheimer’s Disease Research Center at Washington University School of Medicine (Table 1). This evidence concerns the gene MAPT and Brain atrophy.